Compare MDV & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | CVRX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.4M | 179.5M |
| IPO Year | 2022 | 2021 |
| Metric | MDV | CVRX |
|---|---|---|
| Price | $15.04 | $6.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.40 |
| AVG Volume (30 Days) | 35.2K | ★ 398.5K |
| Earning Date | 03-03-2026 | 02-12-2026 |
| Dividend Yield | ★ 7.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $47,479,000.00 | ★ $55,969,000.00 |
| Revenue This Year | $0.13 | $11.91 |
| Revenue Next Year | $0.71 | $15.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.44 |
| 52 Week Low | $13.62 | $4.30 |
| 52 Week High | $17.15 | $16.59 |
| Indicator | MDV | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 47.32 |
| Support Level | $14.93 | $6.59 |
| Resistance Level | $15.51 | $7.42 |
| Average True Range (ATR) | 0.34 | 0.71 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 65.22 | 67.03 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.